Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Radiol Oncol ; 53(4): 388-396, 2019 10 25.
Artículo en Inglés | MEDLINE | ID: mdl-31652121

RESUMEN

Background Childhood and adult-onset craniopharyngioma is a rare embryogenic tumor of the sellar, suprasellar, and parasellar region. Survival rates are high; however, tumor location and treatment sequalae including endocrine deficits, visual impairment, metabolic complications, cognitive and psychosocial deficits can significantly impair patient's quality of life. There is considerable controversy regarding the optimal management of craniopharyngiomas. Subtotal resection of the tumor followed by targeted irradiation to avoid further hypothalamic damage is currently indicated. Novel insights in the tumor's molecular pathology present the possibility for targeted therapy possibly decreasing the rate and severity of treatment-associated morbidity. Conclusions Craniopharyngioma should be seen as a chronic disease. To achieve optimal outcomes a multidisciplinary team of specialized neurosurgeons, neuro-radiologists, neuro-oncologists, pathologists and endocrinologists should be involved in the diagnosis, planning of the surgery, irradiation and long-term follow-up.


Asunto(s)
Craneofaringioma/diagnóstico por imagen , Enfermedades Hipotalámicas/fisiopatología , Hipotálamo/diagnóstico por imagen , Imagen por Resonancia Magnética , Obesidad/fisiopatología , Neoplasias Hipofisarias/diagnóstico por imagen , Tomografía Computarizada por Rayos X , Adulto , Edad de Inicio , Niño , Craneofaringioma/complicaciones , Craneofaringioma/patología , Craneofaringioma/radioterapia , Progresión de la Enfermedad , Humanos , Enfermedades Hipotalámicas/terapia , Hipotálamo/fisiopatología , Clasificación del Tumor , Obesidad/terapia , Neoplasias Hipofisarias/complicaciones , Neoplasias Hipofisarias/patología , Neoplasias Hipofisarias/radioterapia , Pronóstico , Calidad de Vida , Radiocirugia , Tasa de Supervivencia
2.
Expert Rev Neurother ; 18(10): 793-806, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-30257123

RESUMEN

INTRODUCTION: Childhood-onset craniopharyngiomas are rare embryonic tumors of low-grade histological malignancy. Severe obesity, physical fatigue, and psychosocial deficits due to hypothalamic tumor involvement have negative impact on quality of life. Initial pretreatment involvement of hypothalamic structures and/or treatment-related lesions result in sequelae clinically associated with impaired social and physical functionality and severe neuroendocrine deficiencies. Overall and progression-free survival rates are not associated with the degree of surgical resection. However, reduced overall survival rates were observed in patients with primary hypothalamic tumor involvement. Areas covered: This review discusses new perspectives on diagnostics, treatment, and follow-up of patients with childhood-onset craniopharyngioma, which were mostly published after 2010 and presented at the 5th International Multidisciplinary Postgraduate Course on Childhood Craniopharyngioma, 19-22 April 2018, at Bad Zwischenahn, Germany. Expert commentary: Percutaneous radio-oncological treatment options are effective in prevention of relapses and tumor progressions. Initial experience with proton beam therapy in childhood-onset craniopharyngioma patients shows promising results in terms of more protective radiological treatment. Recent reports on the molecular pathogenesis of craniopharyngioma open perspectives on the possibility of testing novel treatments targeting pathogenic pathways. As long as effective treatment options for hypothalamic syndrome are not available, hypothalamus-sparing treatment strategies are recommended.


Asunto(s)
Craneofaringioma , Neoplasias Hipofisarias , Edad de Inicio , Niño , Craneofaringioma/diagnóstico , Craneofaringioma/patología , Craneofaringioma/radioterapia , Craneofaringioma/cirugía , Progresión de la Enfermedad , Humanos , Hipotálamo/patología , Hipotálamo/cirugía , Recurrencia Local de Neoplasia/prevención & control , Neoplasias Hipofisarias/diagnóstico , Neoplasias Hipofisarias/patología , Neoplasias Hipofisarias/radioterapia , Neoplasias Hipofisarias/cirugía , Calidad de Vida , Dosificación Radioterapéutica , Tasa de Supervivencia , Resultado del Tratamiento
3.
Endocrine ; 51(1): 148-62, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26179178

RESUMEN

Quality of life of craniopharyngioma patients can be severely impaired by derangement of hypothalamic function. A classification, taking into account preoperative hypothalamic damage, evaluated by magnetic resonance imaging (MRI), and correlating it with postoperative weight change is still missing in the literature. The aim of our study is to identify objective radiological criteria as preoperative prognostic factors for hypothalamic damage. Pre- and post-operative MRI and clinical data of 47 patients, treated at our Institution for craniopharyngioma, were retrospectively analyzed, based on radiological variables, identified as prognostic factor for hypothalamic involvement. Main factors associated with postoperative obesity were hypothalamic hyperintensity in T2-weighted/FLAIR imaging (p < 0.033), mammillary body involvement according to Müller classification (p < 0.020), unidentifiable pituitary stalk (p < 0.001), dislocated chiasm (p < 0.038), either not visible infundibular recess (p < 0.019) or unrecognizable supra-optic recess (p < 0.004), and retrochiasmatic tumor extension (p < 0.019). Accordingly, postoperative hypothalamic syndrome was associated with peritumoral edema in T2-weighted/FLAIR images (p < 0.003), unidentifiable hypothalamus (p < 0.024), hypothalamic compression (p < 0.006), fornix displacement (p < 0.032), and unrecognizable supra-optic recess (p < 0.031). Ultimately, variables identified as predictive factors of postoperative hypothalamic syndrome were the degree of hypothalamic involvement according to the classification described by Sainte-Rose and Puget (p < 0.002; grade 0 vs 2 p < 0.001), Van Gompel (p < 0.002; grade 0 vs 1, p < 0.027; and grade 0 vs 2, p < 0.002), and Muller (p < 0.006; grade 0 vs 1, p < 0.05; and grade 0 vs 2, p < 0.004). The identification of these predictive factors will help to define and score the preoperative hypothalamic involvement in craniopharyngioma patients.


Asunto(s)
Craneofaringioma/diagnóstico , Craneofaringioma/cirugía , Hipotálamo/fisiopatología , Imagen por Resonancia Magnética , Neoplasias Hipofisarias/diagnóstico , Neoplasias Hipofisarias/cirugía , Adulto , Niño , Craneofaringioma/mortalidad , Craneofaringioma/radioterapia , Femenino , Humanos , Hipotálamo/patología , Masculino , Neoplasias Hipofisarias/mortalidad , Neoplasias Hipofisarias/radioterapia , Valor Predictivo de las Pruebas , Pronóstico , Calidad de Vida , Estudios Retrospectivos , Resultado del Tratamiento
4.
Int J Radiat Oncol Biol Phys ; 84(4): 990-5, 2012 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-22483696

RESUMEN

PURPOSE: To develop a mathematical model utilizing more readily available measures than stimulation tests that identifies brain tumor survivors with high likelihood of abnormal growth hormone secretion after radiotherapy (RT), to avoid late recognition and a consequent delay in growth hormone replacement therapy. METHODS AND MATERIALS: We analyzed 191 prospectively collected post-RT evaluations of peak growth hormone level (arginine tolerance/levodopa stimulation test), serum insulin-like growth factor 1 (IGF-1), IGF-binding protein 3, height, weight, growth velocity, and body mass index in 106 children and adolescents treated for ependymoma (n=72), low-grade glioma (n=28) or craniopharyngioma (n=6), who had normal growth hormone levels before RT. Normal level in this study was defined as the peak growth hormone response to the stimulation test≥7 ng/mL. RESULTS: Independent predictor variables identified by multivariate logistic regression with high statistical significance (p<0.0001) included IGF-1 z score, weight z score, and hypothalamic dose. The developed predictive model demonstrated a strong discriminatory power with an area under the receiver operating characteristic curve of 0.883. At a potential cutoff point of probability of 0.3 the sensitivity was 80% and specificity 78%. CONCLUSIONS: Without unpleasant and expensive frequent stimulation tests, our model provides a quantitative approach to closely follow the growth hormone secretory capacity of brain tumor survivors. It allows identification of high-risk children for subsequent confirmatory tests and in-depth workup for diagnosis of growth hormone deficiency.


Asunto(s)
Neoplasias Encefálicas/metabolismo , Neoplasias Encefálicas/radioterapia , Hormona de Crecimiento Humana/metabolismo , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/metabolismo , Factor I del Crecimiento Similar a la Insulina/metabolismo , Modelos Biológicos , Adolescente , Arginina , Biomarcadores/metabolismo , Niño , Preescolar , Craneofaringioma/metabolismo , Craneofaringioma/radioterapia , Ependimoma/metabolismo , Ependimoma/radioterapia , Estudios de Factibilidad , Femenino , Glioma/metabolismo , Glioma/radioterapia , Hormona de Crecimiento Humana/deficiencia , Humanos , Hipotálamo/efectos de la radiación , Lactante , Levodopa , Modelos Logísticos , Masculino , Valor Predictivo de las Pruebas , Probabilidad , Estudios Prospectivos , Curva ROC , Planificación de la Radioterapia Asistida por Computador/métodos , Radioterapia Conformacional , Sensibilidad y Especificidad
5.
Radiother Oncol ; 82(1): 90-5, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17161483

RESUMEN

PURPOSE: To describe the technique and results of stereotactically guided conformal radiotherapy (SCRT) in patients with craniopharyngioma after conservative surgery. METHODS AND MATERIALS: Thirty-nine patients with craniopharyngioma aged 3-68 years (median age 18 years) were treated with SCRT between June 1994 and January 2003. All patients were referred for radiotherapy after undergoing one or more surgical procedures. Treatment was delivered in 30-33 daily fractions over 6-6.5 weeks to a total dose of 50 Gy using 6 MV photons. Outcome was assessed prospectively. RESULTS: At a median follow-up of 40 months (range 3-88 months) the 3- and 5-year progression-free survival (PFS) was 97% and 92%, and 3- and 5-year survival 100%. Two patients required further debulking surgery for progressive disease 8 and 41 months after radiotherapy. Twelve patients (30%) had acute clinical deterioration due to cystic enlargement of craniopharyngioma following SCRT and required cyst aspiration. One patient with severe visual impairment prior to radiotherapy had visual deterioration following SCRT. Seven out of 10 patients with a normal pituitary function before SCRT had no endocrine deficits following treatment. CONCLUSION: SCRT as a high-precision technique of localized RT is suitable for the treatment of incompletely excised craniopharyngioma. The local control, toxicity and survival outcomes are comparable to results reported following conventional external beam RT. Longer follow-up is required to assess long-term efficacy and toxicity, particularly in terms of potential reduction in treatment related late toxicity.


Asunto(s)
Craneofaringioma/radioterapia , Neoplasias Hipofisarias/radioterapia , Radioterapia Conformacional/métodos , Adolescente , Adulto , Anciano , Niño , Preescolar , Craneofaringioma/cirugía , Supervivencia sin Enfermedad , Fraccionamiento de la Dosis de Radiación , Femenino , Estudios de Seguimiento , Humanos , Hipotálamo/efectos de la radiación , Masculino , Persona de Mediana Edad , Hipófisis/efectos de la radiación , Neoplasias Hipofisarias/cirugía , Planificación de la Radioterapia Asistida por Computador , Radioterapia Adyuvante , Radioterapia Conformacional/efectos adversos , Resultado del Tratamiento , Visión Ocular/efectos de la radiación
6.
J Pediatr Endocrinol Metab ; 19 Suppl 1: 367-70, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16700312

RESUMEN

Craniopharyngiomas remain a therapeutic challenge in terms of treatment-related morbidity. The fact that they are rare, that they are histologically benign, and that anatomically they are located in a challenging area, made them worthy surgical prizes. Whilst surgery has allowed us to meet the challenge of visual salvage, and the advances in hormone replacement therapy are addressing the endocrine challenge, we are becoming increasingly aware that for many children radical resection comes with the cost of devastating effects on quality of life. Increasingly we are recognizing that the next challenge is preservation of hypothalamic function. This consciousness of the morbidity of radical resection has led us, like many pediatric units, to re-examine multimodal treatment strategies. This review examines the Necker experience, aiming to analyze the factors influencing our decision making for treatment.


Asunto(s)
Craneofaringioma/terapia , Neoplasias Hipofisarias/terapia , Terapia Combinada , Craneofaringioma/radioterapia , Craneofaringioma/cirugía , Humanos , Hipotálamo/fisiopatología , Procedimientos Neuroquirúrgicos , Neoplasias Hipofisarias/radioterapia , Neoplasias Hipofisarias/cirugía , Calidad de Vida , Medición de Riesgo , Resultado del Tratamiento
7.
Childs Nerv Syst ; 21(11): 975-80, 2005 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-16075216

RESUMEN

OBJECTS: We longitudinally analysed functional capacity and quality of life (QoL) in 102 patients with a childhood craniopharyngioma during follow-up. METHODS: The Fertigkeitenskala Münster-Heidelberg (FMH) ability scale was used for QoL assessment. Multivariate analysis evaluated FMH scores at various time points, examining hypothalamus involvement (HI), body mass index (BMI), degree of resection, tumour progression, relapse and irradiation. RESULTS AND CONCLUSION: Patients without HI (n=60) self-assessed higher QoL at baseline (p=0.001) and follow-up (p<0.001) than patients with HI (n=42). Only patients without HI evaluated at baseline >12 months after diagnosis showed longitudinal improvement in FMH scores (p=0.040). Rates of incomplete resection and irradiation were higher (p=0.070 and p=0.002 respectively) in patients with HI. In multivariate analysis, only HI, tumour relapse, progression, baseline FMH score, and time between diagnosis and baseline evaluation had independent impact on QoL. HI, tumour progression, and relapse had long-term QoL affects-most notably, severe obesity.


Asunto(s)
Craneofaringioma/psicología , Hipofisectomía/psicología , Neoplasias Hipofisarias/psicología , Calidad de Vida/psicología , Sobrevivientes/psicología , Actividades Cotidianas/clasificación , Actividades Cotidianas/psicología , Adolescente , Adulto , Índice de Masa Corporal , Niño , Preescolar , Terapia Combinada , Craneofaringioma/radioterapia , Craneofaringioma/cirugía , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Hipotálamo/patología , Lactante , Estudios Longitudinales , Masculino , Invasividad Neoplásica , Recurrencia Local de Neoplasia/psicología , Obesidad/psicología , Irradiación Hipofisaria , Neoplasias Hipofisarias/radioterapia , Neoplasias Hipofisarias/cirugía , Complicaciones Posoperatorias/psicología , Psicometría/estadística & datos numéricos , Radioterapia Adyuvante , Reproducibilidad de los Resultados , Autoevaluación (Psicología) , Perfil de Impacto de Enfermedad
8.
Klin Padiatr ; 216(6): 343-8, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15565549

RESUMEN

The overall survival rate of patients with craniopharyngioma, an embryogenic malformation, is high (0.92 +/- 0.03). However, there is considerable morbidity and impaired quality of life, even when the tumor can be completely resected. Aim of our study was to analyze risk factors for severe obesity (body mass index [BMI] > or = 7 SD) and the prognosis of severely obese survivors of childhood craniopharyngioma recruited in our cross-sectional study on 183 patients (HIT-ENDO) and in the prospective study KRANIOPHARYNGEOM 2000. Severe obesity (BMI > or = 7 SD) was present in 16 % of patients and associated with higher tumor volume (p < 0.05), more frequent neurosurgical interventions (p < 0.05) and a higher rate of hypothalamic involvement (p < 0.001). Self-assessed functional capacity (FMH) was lower (p < 0.001) in severely obese survivors (FMH: median 33, range: 4-64) when compared with normal weight patients (FMH: 50; 1-95). Overall survival (20 years) was lower (p = 0.034) in patients with severe obesity in comparison to patients with moderate obesity and normal weight. Cardiovascular morbidity and mortality was high in severely obese patients. Between 10/01 and 03/04 fifty-seven patients (27 female/30 male) were recruited in KRANIOPHARYNGEOM 2000 (www.kraniopharyngeom.com). The impact of tumor localization (3.2 % intrasellar, 22.6 % suprasellar, 74.2 % combined intra/suprasellar; 51.6 % hypothalamic involvement) and treatment (26 complete resections, 22 partial resections followed by irradiation in one case; primary irradiation after biopsy in one case) on quality of life, functional capacity and prognosis will be evaluated longitudinally and prospectively.


Asunto(s)
Craneofaringioma , Obesidad/etiología , Neoplasias Hipofisarias , Adolescente , Adulto , Índice de Masa Corporal , Niño , Preescolar , Terapia Combinada , Craneofaringioma/complicaciones , Craneofaringioma/mortalidad , Craneofaringioma/radioterapia , Craneofaringioma/cirugía , Estudios Transversales , Interpretación Estadística de Datos , Femenino , Estudios de Seguimiento , Humanos , Hipotálamo , Lactante , Recién Nacido , Masculino , Estudios Multicéntricos como Asunto , Neoplasias Hipofisarias/complicaciones , Neoplasias Hipofisarias/mortalidad , Neoplasias Hipofisarias/radioterapia , Neoplasias Hipofisarias/cirugía , Pronóstico , Estudios Prospectivos , Calidad de Vida , Factores de Riesgo , Análisis de Supervivencia , Factores de Tiempo
9.
J Clin Endocrinol Metab ; 88(2): 611-6, 2003 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-12574189

RESUMEN

Hypothalamic obesity, a syndrome of intractable weight gain due to hypothalamic damage, is an uncommon but devastating complication for children surviving brain tumors. We undertook a retrospective evaluation of the body mass index (BMI) curves for the St. Jude Children's Research Hospital brain tumor population diagnosed between 1965 and 1995 after completion of therapy to determine risk factors for the development of obesity. Inclusion criteria were: diagnosis less than 14 yr of age, no spinal cord involvement, ambulatory, no supraphysiologic hydrocortisone therapy (>12 mg/m(2) x d), treatment and follow-up at St. Jude Children's Research Hospital, and disease-free survival greater than 5 yr (n = 148). Risk factors examined were age at diagnosis, tumor location, histology, extent of surgery, hydrocephalus requiring ventriculoperitoneal shunting, initial high-dose glucocorticoids, cranial radiation therapy, radiation dosimetry to the hypothalamus, intrathecal chemotherapy, and presence of endocrinopathy. Analyses were performed both between groups within a risk factor and against BMI changes for age in normal children older than 5.5 yr (the age of adiposity rebound). Risk factors were: age at diagnosis (P = 0.04), radiation dosimetry to the hypothalamus (51-72 Gy, P = 0.002 even after hypothalamic and thalamic tumor exclusion), and presence of any endocrinopathy (P = 0.03). In addition, risk factors when compared with BMI slope for the general American pediatric population included: tumor location (hypothalamic, P = 0.001), tumor histology (craniopharyngioma, P = 0.009; pilocytic astrocytoma, P = 0.043; medulloblastoma, P = 0.039); and extent of surgery (biopsy, P = 0.03; subtotal resection, P = 0.018). These results verify hypothalamic damage, either due to tumor, surgery, or radiation, as the primary cause of obesity in survivors of childhood brain tumors. In particular, hypothalamic radiation doses of more than 51 Gy are permissive. These results reiterate the importance of the hypothalamus in energy balance, provide risk assessment criteria for preventative measures before the development of obesity in at-risk patients, and suggest therapeutic strategies to reduce the future development of obesity.


Asunto(s)
Neoplasias Encefálicas/epidemiología , Craneofaringioma/epidemiología , Obesidad/epidemiología , Astrocitoma/tratamiento farmacológico , Astrocitoma/epidemiología , Astrocitoma/radioterapia , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/radioterapia , Neoplasias Cerebelosas/tratamiento farmacológico , Neoplasias Cerebelosas/epidemiología , Neoplasias Cerebelosas/radioterapia , Niño , Preescolar , Craneofaringioma/tratamiento farmacológico , Craneofaringioma/radioterapia , Supervivencia sin Enfermedad , Humanos , Hipotálamo/fisiología , Meduloblastoma/tratamiento farmacológico , Meduloblastoma/epidemiología , Meduloblastoma/radioterapia , Estudios Retrospectivos , Factores de Riesgo
10.
Acta Neurochir (Wien) ; 140(5): 447-54, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9728244

RESUMEN

Although histologically benign, craniopharyngioma can regrow either from macroscopic remnants of the tumour left behind at operation, or even after an apparently gross total removal. Recurrence rates vary significantly in the literature, depending on the efficacy of surgical treatment and also on the growth potential of the tumour itself. The main factor influencing tumour regrowth is obviously the extent of surgical resection, as total removal carries a much lesser risk of recurrence compared to subtotal or partial resections (although in such cases radiation therapy can lower this risk significantly). Other factors involved are the duration of follow-up and patient's age at operation, as children tend to relapse more frequently than adults. Even in the "microsurgery" era, characterized by high percentages of total resections, recurrences remain high and continue to represent a major problem of craniopharyngioma treatment. Twenty-seven children and adolescents were operated on for craniopharyngioma at the Department of Neurosurgery, Section of Pediatric Neurosurgery, Catholic University Medical School, Rome between June 1985 and June 1997. Total tumour resection was achieved in 18 cases, subtotal in 7 and partial in 2 instances. One patient died post-operatively. Post-operative neuroradiological investigations confirmed the operative findings, although 3 children with an apparently gross total removal showed a residual non-enhancing calcium fleck adherent to the hypothalamus (which remained stable at the following examinations). Three of the 9 patients with less than total removal underwent post-operative radiation therapy. Out of the 26 surviving patients 6 presented a recurrence of their craniopharyngioma, 2 after an apparently gross total removal and 4 after a subtotal or partial resection (one of them had received radiation therapy). The diagnosis was merely neuroradiological in 5 cases, as only one child presented a clinical picture suggestive of tumour regrowth. Surgery was the first therapeutic option in all the cases. Total tumour resection was accomplished in 3 cases, subtotal in 2 and partial in the last one. One child died post-operatively. Four of the 5 survivors received radiation therapy. All the patients are presently alive and stable (mean follow-up: 5.6 yrs). The authors conclude that surgery should be the first therapeutic option in case of recurrent craniopharyngioma and that radiation therapy should also be considered but only as adjuvant therapy.


Asunto(s)
Craneofaringioma/cirugía , Recurrencia Local de Neoplasia/prevención & control , Adolescente , Niño , Preescolar , Terapia Combinada , Craneofaringioma/diagnóstico , Craneofaringioma/radioterapia , Femenino , Estudios de Seguimiento , Humanos , Lactante , Imagen por Resonancia Magnética , Masculino , Recurrencia Local de Neoplasia/radioterapia , Recurrencia Local de Neoplasia/cirugía , Neoplasia Residual , Selección de Paciente , Neoplasias Hipofisarias/diagnóstico , Neoplasias Hipofisarias/radioterapia , Neoplasias Hipofisarias/cirugía , Complicaciones Posoperatorias , Radioterapia Adyuvante , Reoperación/métodos , Factores de Tiempo , Resultado del Tratamiento
11.
J Neurosurg ; 77(4): 545-50, 1992 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-1527612

RESUMEN

Visual function, endocrinological status, and radiological outcome are reported in 31 patients harboring a cystic craniopharyngioma, who underwent 35 intracavitary brachytherapy procedures with yttrium-90. In 26 of these patients intracavitary brachytherapy was the primary treatment. The follow-up period ranged from 2 to 80 months (41 +/- 22 months, mean +/- standard deviation). Five patients died from tumor-related causes. Endocrine recovery was modest. Prior to brachytherapy, visual acuity was diminished in 38 eyes and field defects were present in 46. Funduscopy before treatment revealed optic atrophy in 47% of the eyes. Visual acuity improved in 29% of the eyes studied, remained stable in 13%, and deteriorated in 58%. Visual field defects improved in 28% of the eyes studied, remained stable in 20%, and deteriorated in 52%. The possible causes for deterioration in visual function are discussed. Complete resolution of 10 cysts was noted. In 12 patients the size of the cyst decreased; however, in three of these patients new cyst formation took place. The cyst size stabilized in six cases and increased in three. Although there is still a substantial degree of visual function deterioration following intracavitary brachytherapy, morbidity is otherwise low, making this treatment modality a reasonable alternative to craniotomy.


Asunto(s)
Braquiterapia , Craneofaringioma/radioterapia , Neoplasias Hipofisarias/radioterapia , Radioisótopos de Itrio/administración & dosificación , Adolescente , Adulto , Braquiterapia/efectos adversos , Niño , Preescolar , Craneofaringioma/complicaciones , Craneofaringioma/diagnóstico por imagen , Craneofaringioma/mortalidad , Enfermedades del Sistema Endocrino/etiología , Oftalmopatías/etiología , Oftalmopatías/fisiopatología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Neoplasias Hipofisarias/complicaciones , Neoplasias Hipofisarias/diagnóstico por imagen , Neoplasias Hipofisarias/mortalidad , Calidad de Vida , Tasa de Supervivencia , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Agudeza Visual/fisiología , Campos Visuales/fisiología
13.
Cancer ; 35(1): 111-20, 1975 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-162849

RESUMEN

Three types of tumor (supratentorial astrocytoma, medulloblastoma, and craniopharyngioma), each requiring a fundamentally different therapeutic approach, will be used to illustrate the principles and practice of combined treatment in this field. The role of radiotherapy and ways of enhancing the effect of irradiation will be considered. Attention will be given to adjuvant chemotherapy and to multiple drug regimes. Reference will be made to an early effort at immunotherapy following the initial reduction of tumor cell load by surgery and irradiation.


Asunto(s)
Astrocitoma/terapia , Neoplasias Encefálicas/terapia , Craneofaringioma/terapia , Meduloblastoma/terapia , Antígenos de Neoplasias , Antineoplásicos/uso terapéutico , Astrocitoma/radioterapia , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/radioterapia , Carmustina/uso terapéutico , Niño , Craneofaringioma/radioterapia , Craneofaringioma/cirugía , Glioblastoma/radioterapia , Glioma/radioterapia , Humanos , Oxigenoterapia Hiperbárica , Hipotermia Inducida , Inmunoterapia , Meduloblastoma/tratamiento farmacológico , Meduloblastoma/radioterapia , Neutrones , Compuestos de Nitrosourea/uso terapéutico , Fármacos Sensibilizantes a Radiaciones , Dosificación Radioterapéutica , Radioterapia de Alta Energía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA